Key Highlights
- KRYS reported third quarter net Revenue of $127.3 million, up 30% from $97.8 million a year earlier.
- Net income was $63.1 million, or $2.05 per diluted share, compared with $79.4 million, or $2.66, in the third quarter of 2025.
- Income from operations rose to $71.1 million from $41.4 million.
- The board authorized a share repurchase program of up to $400 million in October 2026.
- Cash and investments exceeded $1.2 billion at the end of September 2026.
Vyjuvek Revenue Climbs 30% to $127.3 Million as International Sales Reach $32 Million
Krystal Biotech (NASDAQ:KRYS) reported results for the quarter ended Sep 30, 2026 on Nov 2, 2026. Net revenue, all from its gene therapy Vyjuvek, was $127.3 million, compared with $97.8 million in the same quarter of 2025. Nine-month revenue was $362.9 million versus $282.0 million.
Krystal is a commercial-stage company that develops gene therapies, and Vyjuvek treats dystrophic epidermolysis bullosa, a rare genetic skin disease. US net revenue was $95.3 million, supported by more than 760 reimbursement approvals and over 80 new prescribers added in the quarter. About 80% of US patients now self-administer the treatment.
International revenue reached about $32 million, helped by launches in Europe and Japan. Management said pricing talks have concluded in Germany and Italy, with an Italian launch expected in early 2027, and a Spanish pricing decision is expected before the end of 2026.
Operating Income Jumps 72% but Net Income Faces a Prior-Year Tax Benefit
Income from operations rose to $71.1 million from $41.4 million, an increase of 72% (calculated). Net income was $63.1 million, or $2.05 per diluted share, against $79.4 million, or $2.66, a year earlier.
The prior-year quarter included a $31.4 million income tax benefit, while the latest quarter carried $17.1 million of tax expense. Management said last year's results reflected the release of most of a valuation allowance on deferred tax Assets and the Reversal of a research expense Capitalization rule, both nonrecurring.
Gross Margin was 94%, down from 96%, as European and Japanese sales do not yet benefit from the Manufacturing process optimizations approved in the US. Cost of Goods Sold was $7.6 million versus $4.3 million. Research and Development expenses were $14.9 million versus $14.6 million, while selling, general and administrative expenses fell to $33.7 million from $37.6 million, partly on insurance reimbursement of legal costs.
$400 Million Buyback and $1.2 Billion Cash Pile Frame Capital Plans
The board authorized a repurchase program of up to $400 million of common stock in October 2026, which management expects to deploy over about two years. Cash and investments exceeded $1.2 billion at Sep 30, 2026, and net cash from Operating Activities for the nine months was $246.4 million versus $123.4 million.
Krystal lowered its full-year non-GAAP research and development plus selling, general and administrative expense guidance to $155 million to $165 million, from $175 million to $195 million.
Gorlin Syndrome Data and Delayed Readouts Set the Pipeline Calendar
A pilot study of KB113 in three adults with Gorlin syndrome showed regression of more than 80% of assessed lesions, including lesions that were not injected, and Krystal is engaging the FDA on next steps. Management acknowledged that some readouts will take longer than first expected. Hailey-Hailey data is due before year end, interim cystic fibrosis results are expected in the first half of 2027, and top-line results from the registrational eye study for dystrophic epidermolysis bullosa are expected shortly after the last patient visit in February 2027.






Please wait processing your request...